BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 37175943)

  • 21. Familial non-medullary thyroid carcinoma: clinico-pathological features, current knowledge and novelty regarding genetic risk factors.
    Cirello V
    Minerva Endocrinol (Torino); 2021 Mar; 46(1):5-20. PubMed ID: 33045820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Susceptibility Genes and Chromosomal Regions Associated With Non-Syndromic Familial Non-Medullary Thyroid Carcinoma: Some Pathogenetic and Diagnostic Keys.
    Sánchez-Ares M; Cameselle-García S; Abdulkader-Nallib I; Rodríguez-Carnero G; Beiras-Sarasquete C; Puñal-Rodríguez JA; Cameselle-Teijeiro JM
    Front Endocrinol (Lausanne); 2022; 13():829103. PubMed ID: 35295987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Familial follicular cell tumors: classification and morphological characteristics.
    Nosé V
    Endocr Pathol; 2010 Dec; 21(4):219-26. PubMed ID: 20878367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Familial nonmedullary thyroid cancer: screening, clinical, molecular and genetic findings.
    Navas-Carrillo D; Ríos A; Rodríguez JM; Parrilla P; Orenes-Piñero E
    Biochim Biophys Acta; 2014 Dec; 1846(2):468-76. PubMed ID: 25218916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequent and Rare HABP2 Variants Are Not Associated with Increased Susceptibility to Familial Nonmedullary Thyroid Carcinoma in the Spanish Population.
    de Randamie R; Martos-Moreno GÁ; Lumbreras C; Chueca M; Donnay S; Luque M; Regojo RM; Mendiola M; Hardisson D; Argente J; Moreno JC
    Horm Res Paediatr; 2018; 89(6):397-407. PubMed ID: 29895015
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence, clinicopathologic features, and somatic genetic mutation profile in familial versus sporadic nonmedullary thyroid cancer.
    Moses W; Weng J; Kebebew E
    Thyroid; 2011 Apr; 21(4):367-71. PubMed ID: 21190444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Familial non-medullary thyroid carcinoma (FNMTC): analysis of fPTC/PRN, NMTC1, MNG1 and TCO susceptibility loci and identification of somatic BRAF and RAS mutations.
    Cavaco BM; Batista PF; Martins C; Banito A; do Rosário F; Limbert E; Sobrinho LG; Leite V
    Endocr Relat Cancer; 2008 Mar; 15(1):207-15. PubMed ID: 18310288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigating
    Teixeira E; Fernandes C; Bungărdean M; Paula ADC; Lima RT; Batista R; Vinagre J; Sobrinho-Simões M; Máximo V; Soares P
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of
    Jiang YJ; Xia Y; Hu YX; Han ZJ; Guo AY; Huang T
    Thyroid; 2024 May; 34(5):583-597. PubMed ID: 38411500
    [No Abstract]   [Full Text] [Related]  

  • 30. Familial non-medullary thyroid carcinoma: an update.
    Nosé V
    Endocr Pathol; 2008; 19(4):226-40. PubMed ID: 18931957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical features and genetic predisposition to hereditary nonmedullary thyroid cancer.
    Vriens MR; Suh I; Moses W; Kebebew E
    Thyroid; 2009 Dec; 19(12):1343-9. PubMed ID: 20001717
    [